Responses according to predominant site of disease, were as follows: liver, 12 of 24 patients (50%); nodes/peritoneum 5 of 12 patients (41.7%); lung 1 of 2 patients and bone 1 of 2 patients. Response rates did not significantly differ according to number of metastatic sites: one site, 6 of 11 patients (54.5%); two sites, 9 of 19 patients

(47.4%); and three or more sites, 4 of 10 patients (40%). Responses were seen in 2 of 6 patients (33.3%) who received adjuvant Dactolisib nmr chemotherapy and in 17 of 34 patients (50%) not previously treated with chemotherapy. Responses were observed also in 13 of 28 patients (46.4%) with primary tumor not resected and in 6 of 12 patients (50%) with primary tumor resected. RR did non differ when patients were evaluated according to the primary site of disease (gastric: 46.7% and GEJ: 50%, respectively). The median time for response was 6 weeks (range, 6–18). Upon disease progression, 22 patients (55%) received check details PHA-848125 mw a second-line chemotherapy, including irinotecan/fluorouracil-leucovorin (n = 18) and cisplatin/capecitabine (n = 4). Median TTP was 6.3 months (95% CI 5.4–7.2) (Figure 1). Only 8 patients (20%) progressed within the first two

months, whereas at the time of this analysis all but one patient had experienced progressive disease. Median OS was 12.1 months (95% CI 10.7–13.5 months) (Figure 2). One- and 2-year survivals were 50.3% and 12.6%, respectively. Thirty-six patients had died at the time of the present evaluation. Figure 1 Time to progression for all patients. Figure 2 Overall survival for all patients. Table 2 Objective response in 40 patients Response No. of patients % Complete response * 2 5 Partial response * 17 42.5 Stable disease * 13 32.5 Progressive disease 8 20 * Disease control: 80% Toxicity Hematological toxicity

data are listed in Table 3. A total of 220 cycles of this epirubicin, oxaliplatin and docetaxel (EOD) combination were analyzed in 40 patients, with a stiripentol median of 6 cycles administered per patient (range, 2–8 cycles). The most important toxicity was myelosuppression, which occurred almost always on day 8 (docetaxel nadir). Grade 3 and 4 neutropenia were recorded in 35% and in 15% of the patients, respectively. Febrile neutropenia occurred in 2 (5%) patients. In these patients a 25% dose-reduction of docetaxel was required, whereas treatment was postponed in 2 (5%) patients and in 7 (3.2%) cycles because of a delay in bone marrow recovery. Mean epirubicin, docetaxel and oxaliplatin dose-intensities were 16.19, 18.48 and 31.90 mg/m2/week, respectively, which are equivalent at 97.2%, 92.4% and 95.7% of the planned dose-intensities for these drugs. Grade 3 thrombocytopenia was observed in 2.5% of the patients, and grade 3 anemia occurred in 10% of the patients. Table 3 Grade 3/4 hematological toxicity per cycle and per patient Toxicity % of 220 cycles % of 40 patients   Grade 3 Grade 4 Grade 3 Grade 4 Neutropenia 20 10 35 15 Thrombocytopenia 1 – 2.